仙乐健康始终将创新作为发展根基。公司拥有159项专利，94项发明专利，以及众多保健食品注册证书 和备案凭证。平台创新上，EverBio 益生菌技术平台发布，自主益生菌AKK ONE 获美国GRAS安全认 证，"荔枝元 （LychOtics ）"荣获"年度肠道健康成分"奖项。在细分领域持续深耕，打造出多领域产品 矩阵。品牌建设层面，公司高频亮相行业盛会，强化技术标杆地位。 中证报中证网讯（王珞）8月25日晚间，仙乐健康（300791）（300791）发布2025年半年度报告。报告 显示，公司上半年营业收入达20.42亿元，同比增长2.57%；归属于上市公司股东的净利润为1.61亿元， 同比增长4.30%；扣非后净利润1.59亿元，同比增长3.25%。 面对智能制造的产业趋势，仙乐健康大力推进AI与业务融合，多个智能化项目逐步落地。与AI头部企 业合作建设"AI+功能营养平台"，启用汕头智慧物流中心，推出AI赋能功能营养平台，启动全球黑灯工 厂与智能制造蓝图。公司正从传统CDMO向"营养科技企业"转型。 在业务布局上，仙乐健康积极推进结构优化与全球拓展。中国区全面拥抱新消费趋势，直播电商、跨境 电商等新消费渠道营 ...

Core Viewpoint - Xianle Health reported a steady growth in revenue and net profit for the first half of 2025, reflecting a robust adaptation to new consumer trends and a balanced development structure in the Chinese market [1][2]. Financial Performance - The company achieved a revenue of 2.042 billion yuan, representing a year-on-year increase of 2.57% [1]. - The net profit attributable to shareholders was 161 million yuan, up 4.3% year-on-year [1]. - The net profit after deducting non-recurring items was 159 million yuan, with a growth of 3.25% [1]. New Consumer Trends - Xianle Health embraced new consumption trends, with significant breakthroughs in live e-commerce, cross-border e-commerce, private domain, and new retail channels [1]. - Revenue from new consumer clients grew by over 40%, with their contribution to total revenue approaching 50% [1]. Product Development - The company launched 10 major products in the first half of the year and has 25 reserve products in the pipeline, targeting core customer groups such as children, women, and working professionals [2]. - Xianle Health entered the pet nutrition sector, leveraging human technology for pet applications, aiming to create high-end nutritional solutions for pets [2]. Global Expansion - The company achieved breakthroughs in the Americas, Europe, and Asia-Pacific markets, showcasing a "multi-point flowering" strategy [2]. - The European market exceeded sales targets with double-digit growth, adding two new clients with sales exceeding one million euros and establishing a sales entity in the UK [2]. Innovation and Patents - As of June 30, the company held 159 patents, including 94 invention patents, and had 112 health food registration certificates [3]. - Xianle Health actively participated in international industry events to strengthen its technical benchmark position among global B-end clients [3]. Future Strategy - The company plans to leverage its "technology + manufacturing + globalization" advantages to continuously release long-term value during industrial upgrades [3]. - Xianle Health aims to define the global competitiveness of Chinese enterprises through practical actions and innovation [3].

Core Viewpoint - The company reported a steady growth in revenue and net profit for the first half of 2025, with a focus on expanding its market presence and enhancing brand recognition through strategic initiatives [1][4]. Financial Performance - In 25H1, the company achieved operating revenue of 2.042 billion yuan, a year-on-year increase of 2.57%, and a net profit attributable to shareholders of 161 million yuan, up 4.30% year-on-year [1]. - The second quarter of 2025 saw operating revenue of 1.087 billion yuan, reflecting a year-on-year growth of 4.66%, with a net profit of 92 million yuan, an increase of 1.13% [1]. - The gross profit margin for 25H1 was 33.18%, with a slight increase in the second quarter to 33.27% [3]. Segment Performance - By dosage form, soft capsules generated revenue of 947 million yuan (up 6.47%), gummies at 517 million yuan (up 6.35%), tablets at 189 million yuan (up 33.37%), while beverages and powders saw declines of 20.84% and 36.02%, respectively [1]. - Regionally, the China segment reported revenue of 818 million yuan (down 1.63%), while the Americas and Europe segments grew by 4.26% and 21.96%, respectively [1]. Strategic Initiatives - The company is focusing on developing new consumer markets, with new consumption customer revenue growth exceeding 40% in 25H1, despite challenges in traditional segments [2]. - The Americas division is expanding its gummy business and targeting new customers in Latin America, particularly in Brazil [2]. - The European division is actively pursuing new clients and products, particularly in the UK market [2]. - The Asia-Pacific division is enhancing partnerships with key clients in Australia and preparing for market expansion in Russia and Japan [2]. Brand and Market Development - The company participated in 12 domestic and international forums and exhibitions in 25H1 to enhance brand visibility and industry influence [4]. - Key breakthroughs were achieved in probiotics and anti-aging sectors, with the launch of the EverBio platform and the GRAS certification for its proprietary probiotics [4]. - The company is also focusing on the pet nutrition market, having participated in the Asia Pet Expo in August 2025 [4]. Global Business Resilience - The company's global business strategy has demonstrated resilience, with strong performance in the Americas and Europe despite tariff fluctuations [6]. - The ongoing construction of a factory in Thailand is expected to further enhance the company's market presence in Southeast Asia [6].

2025年8月26日，仙乐健康(300791.SZ)发布2025年半年度报告。截至2025年8月25日，共有12个机构投 资者披露持有仙乐健康A股股份，合计持股量达1.58亿股，占仙乐健康总股本的51.33%。其中，前十大 机构投资者包括广东光辉投资有限公司、玄元私募基金投资管理(广东)有限公司-玄元科新273号私募证 券投资基金、珠海阿巴马私募基金投资管理有限公司-阿巴马悦享红利96号私募证券投资基金、上海君 禾私募基金管理有限公司-君禾星辰二号私募证券投资基金、上海渊泓投资管理有限公司-渊泓上善1号 私募证券投资基金、中国银行股份有限公司-招商产业精选股票型证券投资基金、珠海横琴长乐汇资本 管理有限公司-专享1号私募证券投资基金、上海浦东发展银行股份有限公司-东方红核心价值混合型证 券投资基金、香港中央结算有限公司、银华-道琼斯88指数，前十大机构投资者合计持股比例达 51.25%。相较于上一季度，前十大机构持股比例合计下跌了0.20个百分点。 公募基金方面，本期较上一季度新披露的公募基金共计5个，包括招商产业精选股票A、东方红核心价 值混合A、银华-道琼斯88指数、招商中证消费龙头指数增强A、鑫元国证2 ...

证券研究报告 | 公司点评报告 2025 年 08 月 26 日 仙乐健康（300791.SZ） 营收环比改善，内生利润率提升 消费品/食品饮料 25Q2 公司收入/归母净利润分别同比+4.66%/+1.13%，整体收入端环比改善， BF 亏损扩大，但内生净利率受益于降本增效有所提升。公司锚定全球营养健康 食品行业 CDMO 龙头，积极探索完善产品矩阵寻求开发更多客户，洞察需求提 升成长能力。同时公司前瞻布局高潜赛道，聚焦孕婴童、女性、益生菌与现代 汉方等前沿领域打造全生命周期营养产品矩阵，前瞻布局宠物赛道，打造"人 类营养技术迁移+宠物风味场景适配"创新模式，有望支撑未来增长。我们认为 公司 H2 有望延续全年逐季改善的态势，同时建议关注 BF 个护业务剥离进展， 及其带动的盈利能力显著改善的弹性。考虑到 BF 个护业务对亏损扩大对全年 业绩的影响，我们对此前盈利预测有所调整，预计 25-26 年 EPS 分别为 1.17 元、1.35 元，维持"强烈推荐"投资评级。 强烈推荐（维持） 目标估值：NA 当前股价：25.2 元 基础数据 | 总股本（百万股） | 307 | | --- | --- | | 已 ...

证券代码：300791 证券简称：仙乐健康 公告编码：2025-083 证券代码：123113 证券简称：仙乐转债 一、重要提示 本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 资者应当到证监会指定媒体仔细阅读半年度报告全文。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 董事会决议通过的本报告期优先股利润分配预案 □适用 √不适用 公司是否需追溯调整或重述以前年度会计数据 □是 √否 所有董事均已出席了审议本报告的董事会会议。 非标准审计意见提示 □适用 √不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 □适用 √不适用 ■ 3、公司股东数量及持股情况 单位：股 ■ 注1：林培青先生名下持有公司股份28,035,072股，其中，21,902,400股（占公司总股本比例7.11%）为 其自有的公司股份，6,132,672股（占公司总股本比例1.99%）系其作为信托受托人持有的公司股份，其 作为信托受托人持有的公司股份登记在其名下，其仅对该等股份享有表决权，该等股份及其派生股份 （若有）的全部经济利益由信托合同项下的受益人享有。 持股5%以上股东 ...

Core Viewpoint - Xianle Health Technology Co., Ltd. held an investor relations event to discuss the strategic implementation and operational performance for the first half of 2025, engaging with 59 institutional investors [1][2]. Group 1: Operational Performance - In the first half of 2025, the company achieved a revenue of 2.042 billion, representing a year-on-year growth of 2.57% [3][4]. - The net profit attributable to shareholders was 161 million, reflecting a year-on-year increase of 4.30% [3][4]. - The China region reported a revenue of 818 million, a decline of 1.63%, while new consumer orders showed significant growth [3]. - The Americas generated 760 million in revenue, up 4.26%, and Europe saw a revenue increase of 21.96% to 359 million [3]. Group 2: Business Segments - The core strategic soft capsule segment grew by 6.5%, benefiting from internal business and BF collaboration [4]. - The gummy business also saw a revenue increase of 6.4%, driven by global demand and large export orders [4]. - Tablet sales surged by 33.4%, capitalizing on growth opportunities, while hard capsules grew by 11% [4]. Group 3: Cash Flow and Financial Management - The company reported a 39.7% year-on-year increase in net cash inflow from operating activities, indicating strong cash flow management [4].

（文章来源：证券日报） 证券日报网讯 8月25日晚间，仙乐健康发布公告称，2025年半年度公司实现营业收入2，041，618， 895.92元，同比增长2.57%；归属于上市公司股东的净利润为161，117，310.35元，同比增长4.30%。 ...

中国区结构优化 8月25日晚间，仙乐健康（300791）披露2025年半年度报告。报告期内，公司实现营业收入20.42亿元， 同比增长2.57%；净利润1.61亿元，同比增长4.30%；扣非净利润1.59亿元，同比增长3.25%。 在全球营养健康产业迈入智能制造与个性化消费并进的发展阶段，仙乐健康凭借新消费渠道的快速起 势、全球布局的多点突破、技术创新的持续输出，以及对未来能力的前瞻性构建，交出了一份兼具战略 定力与创新活力的中期答卷。 新旧动能转换下，仙乐健康全面拥抱新消费趋势，中国市场业务在整体结构上呈现出更均衡、更具韧性 的发展格局，整体订单量实现连续两个季度同比双位数增长。 新消费方面，仙乐健康在直播电商、跨境电商、私域和新零售等渠道均实现强劲突破，新消费客户营收 同比增长超过40%，营收占比已提升至接近50%。其中，借助MCN生态赋能，公司多个新品迅速打爆市 场，打造出高复购、高转化的爆款单品，千万级大客户的新增单品实现了100%份额合作；私域营收增 长超过200%。 与此同时，长青市场方面，仙乐健康坚持"大客户+顾问式服务"策略，持续拓展战略KA合作，推动新产 品试点上市与终端陈列优化，保持合作深 ...

仙乐健康科技股份有限公司 投资者关系活动记录表 证券代码：123113 证券简称：仙乐转债 仙乐健康科技股份有限公司 2025 年 8 月 25 日投资者关系活动记录表 编号： 2025-003 | | ■特定对象调研 □分析师会议 | | --- | --- | | 投资者关系 | □媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | 活动类别 | □现场参观 | | | □其他（ ） | | | 王见鹿（信达资本）、周韵（华安证券）、张潇倩（天风证券）、訾猛（国 | | | 泰海通）、陈力宇（国泰海通）、柴程森（长城基金）、吴林轩（国盛证 | | | 券）、孙天一（浙商证券）、张梓萱（华鑫证券）、黄欣培（财通证券）、 | | | 蒲天瑞（农银汇理）、赵玥（申万资管）、张玉洁（君和资本）、张云（磐 | | | 厚资本）、吴越（华西证券）、王苏煦（汇安基金）、黄亚铷（路博迈基 | | | 金）、任龙（招商证券）、秦一方（国海证券）、韩骋（健顺投资）、杨 | | 参与单位名称 | 逸文（中邮证券）、官忠涛（建信养老金）、董旭（光大保德信）、方勇 | | 及人员姓名 | （开源证券）、童杰（华福 ...